Vericel Corporation  (VCEL)
Other Ticker:  
Price: $36.0000 $0.34 0.953%
Day's High: $36.425 Week Perf: -1.83 %
Day's Low: $ 34.77 30 Day Perf: 4.68 %
Volume (M): 403 52 Wk High: $ 39.90
Volume (M$): $ 14,515 52 Wk Avg: $31.81
Open: $35.51 52 Wk Low: $20.98

 Market Capitalization (Millions $) 1,715
 Shares Outstanding (Millions) 48
 Employees -
 Revenues (TTM) (Millions $) 185
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) 18
 Capital Exp. (TTM) (Millions $) 21

Vericel Corporation
Vericel Corporation is a publicly traded biopharmaceutical company that focuses on developing and commercializing cell therapy products that repair or regenerate human tissue.
The company is headquartered in Cambridge, Massachusetts, and has facilities in Michigan and California.
Vericel's flagship product is called MACI, which stands for Matrix-Induced Autologous Chondrocyte Implantation.
This is a regenerative medicine treatment for patients with knee cartilage damage or disorders.
MACI involves harvesting a patient's own healthy cartilage cells, multiplying them in a laboratory, and then implanting them into the affected area of the knee.
MACI received FDA approval in 2016 and has since been used in thousands of patients.
In addition to MACI, Vericel also sells Epicel, which is a cell-based therapy for treating severe burns.
Epicel involves taking a small sample of a patient's own healthy skin cells, multiplying them in a laboratory, and then grafting them onto the burn wound.
Epicel has been used in over 1,000 patients and is the only FDA-approved cell therapy for the treatment of severe burns.
Vericel has a robust research and development pipeline focused on cell therapy products that target cardiac, pulmonary, and neurological diseases.
The company is committed to advancing science and technology to bring innovative treatments to patients suffering from debilitating conditions.
Overall, Vericel Corporation is a leading player in the field of regenerative medicine, with a focus on developing cell-based therapies that improve patients' quality of life.

   Company Address: 64 Sidney Street Cambridge 2139 MA
   Company Phone Number: 588-5555   Stock Exchange / Ticker: NASDAQ VCEL
   VCEL is expected to report next financial results on February 22, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Twist Bioscience Corporation

Twist Bioscience Corporation Successfully Narrows Deficit, Demonstrating Promising Financial Recovery from July to September 2023

Twist Bioscience Corporation, a leading biotechnology and pharmaceutical company, has showcased strong financial performance in the third quarter of 2023. The company reported a decrease in loss per share, improved income per share, and a significant increase in revenue.
Compared to the previous year, Twist Bioscience Corporation reduced its loss per share from $0.81 to $0.80. Additionally, income per share improved from $1.01 to $0.80 from the previous quarter. These positive results indicate the company's efforts to minimize losses and improve profitability.

Agentix Corp

Article Title: FWDR Announces Second Quarter 2024 Performance, Exhibiting Growth Potential in Biotechnology and Pharmaceuticals Sector

In the fast-paced world of Biotechnology and Pharmaceuticals, where industry leaders often dominate the headlines, it is crucial to keep an eye on lesser-known businesses that may harbor potential for growth and success. One such company, FWDR, recently announced its financial results for the second quarter of 2024, providing some encouraging news and offering investors assurance about its future prospects.
Operating Shortfall Improvement:
FWDR disclosed an operating shortfall of $-0.353155 million for Q2 2024. Although it cannot be considered a significant financial achievement on its own, the fact that it represents an improvement compared to the same period in the previous year is noteworthy. In Q2 2023, FWDR had reported a larger operating shortfall of $-0.42433 million. This improvement indicates the company's commitment to enhancing its financial performance and marks a step in the right direction.

Mymetics Corporation

Mymetics Corporation Faces Challenging Performance in Q3 2023 as Earnings Decline

Financial News Report: Mymetics Corporation Earnings Decline in Q3 2023
Mymetics Corporation, a leading company in the XYZ industry, recently released its financial earnings report for the third quarter of 2023. The results showcase a decline in earnings and revenue compared to the previous year and the previous reporting period.
During the third quarter of 2023, Mymetics Corporation reported earnings per share (EPS) of $0.00. This is the same figure as the previous year but a decrease compared to the previous reporting period. This stagnant growth in earnings per share suggests that the company's profitability remained unchanged.

Redwoods Acquisition Corp

Redwoods Acquisition Corp Roars into Action, Defying Third Quarter Slump

The third quarter financial results for Redwoods Acquisition Corp in 2023 have been released, revealing an operating deficit of -$0.292227 million. This is a significant decrease compared to the operating deficit of -$0.179726 million in the same quarter of the previous year, indicating a decline in the company's financial performance.
To better understand the impact of these results, it is important to analyze the bottom-line figure, which shows a -52.71 percent reduction to $0.729 million in the third quarter of 2023 from the third quarter of 2022. This reduction highlights a substantial decline in the company's earnings during this period.

Creative Medical Technology Holdings Inc

Creative Medical Technology Holdings Inc. Plunges as Q3 2023 Results Reveal Devastating Financial Performance

Financial News Report: CELZ Reports Disastrous Q3 2023; Stock Drops by 0.96% in 5 Trading Days
Creative Medical Technology Holdings Inc. (CELZ) recently reported a disastrous third quarter of 2023, with a significant decline in revenue and an increase in net loss per share compared to the same period a year ago. The company's revenue faded by -89.091% to $0.01 million, while net loss per share swelled to $-1.02, from the corresponding reporting period in the previous year.
For the fiscal time-frame closing September 30, 2023, Creative Medical Technology Holdings Inc. realized a net deficit of $-1.454 million, a significant increase from the $-0.982 million reported in the same period a year ago. The larger net deficit indicates a worsening financial performance for the company.


Vericel's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com